Quantitative imaging and AI-pathology that de-risk every phase, from patient stratification to endpoint readout. Two ways in: by therapeutic area, or by service and capability.
"They turned a dataset I'd have argued about for six months into a decision I could take to the steering committee in two weeks."
Placeholder skeletons. Each shows the intended shape of a populated page. Content to be supplied by the pharma team; claims pass through QARA before anything goes near production.
Liver, pancreas, spleen, kidney and heart measured from a single protocol. Content to be supplied by the pharma team.
[Pharma to supply.]
[Pharma to supply.]
[Pharma to supply.]
MASH, Obesity, Cardiovascular, Renal.
Structured handling of incidental findings across a trial population. Content to be supplied by the pharma team.
[Pharma to supply.]
[Pharma to supply.]
[Pharma to supply.]
All multi-site imaging programmes.
Custom biomarkers and analysis pipelines developed to a sponsor protocol. Content to be supplied by the pharma team.
[Pharma to supply.]
[Pharma to supply.]
[Pharma to supply.]
Sponsor-specific protocols.
Endoscopy capability within the PAIR programme. Content to be supplied by the pharma team.
[Pharma to supply.]
[Pharma to supply.]
[Pharma to supply.]
Gastrointestinal.
Standardised acquisition and storage of trial imaging for later, protocol-defined analysis. Content to be supplied by the pharma team.
[Pharma to supply.]
[Pharma to supply.]
[Pharma to supply.]
Any programme banking imaging for later analysis.
Perspectum's biomarkers are extensively studied non-invasive readouts in liver imaging, peer-reviewed, recognised by regulators, and used in submissions across the UK, US and EU.
See the publication list →Where each biomarker sits with FDA, EMA, MHRA and CE today. Pending items are listed as pending.
View regulator status → Scientific PublicationsAn editorial reading list of the peer-reviewed work behind every biomarker.
View publications → Documentation Regulatory & clinical documentationClearance and conformity documents, quality certification, product manuals and instructions for use.
View regulatory documentation →The full source list and regulatory dossier are available to evaluating sponsors on request.
Talk to our pharma services team. We'll come back with a brief outlining trial design implications and a confidential proposal within five working days.
